RxDoctor Payments Data

Katharine Woessner, MD

Allergy & Immunology · San Diego, CANPI 1184663650

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $425,660 of the $580,852 with a category attached, or 73.3%. 41 manufacturers reported payments, led by GSK at 43.3% of the total. Reporting peaked in 2023 at $140,231 and has fallen 57.9% since, to $59,014 in 2025. Among allergy & immunology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$580,852in general payments, 2019–2025

Across 957 payments — averaging $606.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$252K
  • AstraZeneca$185K
  • Regeneron Healthcare Solutions, Inc.$42K
  • Takeda Pharmaceuticals U.S.A., Inc.$42K
  • Shire North American Group Inc$35K
  • Sanofi$12K
  • plus $14K from 35 others

What the payments were for

  • Consulting fees$79,45214%
  • Speaking & faculty fees$425,66073%
  • Travel & lodging$56,32110%
  • Food & beverage$19,1973%
  • Education$2220%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$580,852 in reported general payments places this provider in the 95th percentile of 426 allergy & immunology providers in California.

See all allergy & immunology providers in California

Medicare billing

Part B allowed, 2024
$810,416
Medicare patients
446
Services billed
40,324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IcatibantIcatibant Acetate16$274,494
XolairOmalizumab58$205,859
Dupixent SyringeDupilumab30$130,404
Dupixent PenDupilumab18$66,922
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$26,818
Spiriva RespimatTiotropium Bromide24$26,415
Breo ElliptaFluticasone/Vilanterol32$21,098
DuleraMometasone/Formoterol23$14,288
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$13,594
Arnuity ElliptaFluticasone Furoate20$9,290
AlvescoCiclesonide11$6,880
Qvar RedihalerBeclomethasone Dipropionate14$5,667
SymbicortBudesonide/Formoterol Fumarate13$5,548
Ipratropium Bromide105$4,951
OdactraMite,d.Farinae-D.Pteronyssinus12$4,034

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$251,682$57,20677 claims
Boehringer IngelheimSpiriva Respimat$141$26,41524 claims
AstraZenecaBreztri Aerosphere, Symbicort$185,454$19,14331 claims
MerckDulera$60$14,28823 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$162$5,66714 claims
Alk-abello, IncOdactra$49$4,03412 claims
PfizerPaxlovid$300$013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 426 allergy & immunology providers in California.

Other allergy & immunology in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →